bacterial vaginosis


Also found in: Medical, Financial, Acronyms, Encyclopedia, Wikipedia.
Related to bacterial vaginosis: trichomoniasis, Yeast infection, metronidazole, chlamydia

bacterial vaginosis

n.
Vaginal infection characterized by a shift from a preponderance of lactobacilli to a preponderance of various anaerobic bacilli in the vagina and by abnormal vaginal discharge.
References in periodicals archive ?
In tubal ligation cases bacterial vaginosis (BV) was the most common (70.
Keywords: bacterial vaginosis, bv, yeast infection, symptoms, discharge, vaginal discharge
Our understanding of bacterial vaginosis (BV) has evolved over many years, yet the condition remains mysterious.
THE FIRST SINGLE-DOSE, oral treatment for bacterial vaginosis will be available by prescription in early 2018, thanks to its approval by the Food and Drug Administration.
Bacterial vaginosis (BV) is an extremely prevalent vaginal condition and the number one cause of vaginitis among both pregnant and non-pregnant women.
Solosec, a five-nitroimidazole antimicrobial agent, had received the approval from the US Food and Drug Administration (FDA) for the treatment of bacterial vaginosis in adult women.
Barbieri for his editorial on effective treatment of recurrent bacterial vaginosis (BV).
US-based biopharmaceutical company Symbiomix has submitted a new drug application for Solosec (secnidazole oral granules) for the treatment of bacterial vaginosis to the US Food and Drug Administration, the company said.
Results: The present study showed maximum incidence of bacterial vaginosis (44%) followed by vulvovaginal candidiasis (25%), non-specific discharge (14%), trichomoniasis (11%), gonorrhea (6%).
vaginalis is almost universally present in the vagina of women with bacterial vaginosis (BV), where it is found with mixed anaerobic flora (2).
Operational characteristics of the clinical diagnosis in the office, with and without tests (pH and amine test), for diagnosing bacterial vaginosis in symptomatic patients in Bogota, Colombia
It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects.